- Home
- ZURA vs NUAI Comparison
ZURA vs NUAI Comparison
Compare ZURA & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZURA | NUAI |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 403.6M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ZURA | NUAI |
|---|---|---|
| Price | $5.57 | $5.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.00 | $11.00 |
| AVG Volume (30 Days) | 679.8K | ★ 6.4M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.89 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $885,400.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 66.18 |
| 52 Week Low | $1.66 | $0.32 |
| 52 Week High | $7.25 | $9.45 |
Technical Indicators
Market Signals| Indicator | ZURA | NUAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 49.93 |
| Support Level | $5.62 | $3.51 |
| Resistance Level | $5.87 | $5.31 |
| Average True Range (ATR) | 0.31 | 0.46 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 53.13 | 62.58 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.